Indoco Remedies Ltd
NSE:INDOCO

Watchlist Manager
Indoco Remedies Ltd Logo
Indoco Remedies Ltd
NSE:INDOCO
Watchlist
Price: 237.19 INR 3.28% Market Closed
Market Cap: 21.9B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one INDOCO stock under the Base Case scenario is 519.36 INR. Compared to the current market price of 237.19 INR, Indoco Remedies Ltd is Undervalued by 54%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INDOCO Relative Value
Base Case
519.36 INR
Undervaluation 54%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.3
P/S
P/S
Price to Sales
1.3
vs History
95
vs Industry
64
Median 3Y
1.9
Median 5Y
2.1
Industry
2.4
Forward
1.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
15
Median 3Y
23.8
Median 5Y
31.2
Industry
20.3
Forward
-48.4
More Details
9.8
P/OCF
P/OCF
Price to OCF
9.8
vs History
76
vs Industry
36
Median 3Y
18.9
Median 5Y
18.9
Industry
15.6
More Details
10.5
P/FCFE
P/FCFE
Price to FCFE
10.5
vs History
57
vs Industry
28
Median 3Y
88.9
Median 5Y
42.7
Industry
23.1
More Details
2
P/B
P/B
Price to Book Value
2
vs History
95
vs Industry
36
Median 3Y
2.9
Median 5Y
3.1
Industry
2
More Details
1.5
EV/S
EV/S
Enterprise Value to Sales
1.5
vs History
95
vs Industry
58
Median 3Y
2
Median 5Y
2.2
Industry
2.5
Forward
1.5
More Details
2.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.2
vs History
95
vs Industry
67
Median 3Y
3
Median 5Y
3.2
Industry
4.8
More Details
17.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.9
vs History
26
vs Industry
20
Median 3Y
13.8
Median 5Y
15.3
Industry
12.5
Forward
18.1
More Details
68.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
68.7
vs History
4
vs Industry
5
Median 3Y
21.8
Median 5Y
22.7
Industry
15.7
Forward
25.8
More Details
11.6
EV/OCF
EV/OCF
Enterprise Value to OCF
11.6
vs History
76
vs Industry
33
Median 3Y
19.1
Median 5Y
19.1
Industry
14.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
2
Median 3Y
-11.3
Median 5Y
-11.3
Industry
17.6
More Details
1.2
EV/IC
EV/IC
Enterprise Value to IC
1.2
vs History
95
vs Industry
48
Median 3Y
2
Median 5Y
2.1
Industry
1.8
More Details

Multiples Across Competitors

INDOCO Competitors Multiples
Indoco Remedies Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Indoco Remedies Ltd
NSE:INDOCO
21.9B INR 1.3 -205.2 17.9 68.7
US
Eli Lilly and Co
NYSE:LLY
783.5B USD 16 70.5 37.8 41.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.1B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 7 20.2 13.3 15.1
CH
Roche Holding AG
SIX:ROG
216.7B CHF 3.6 26.2 9.8 11.5
CH
Novartis AG
SIX:NOVN
182.1B CHF 4.1 17.2 10.2 13.6
UK
AstraZeneca PLC
LSE:AZN
166.7B GBP 4 28.5 130.9 197.4
US
Merck & Co Inc
NYSE:MRK
209.7B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
120.3B EUR 1.3 9.5 5.2 6.1
P/E Multiple
Earnings Growth PEG
IN
Indoco Remedies Ltd
NSE:INDOCO
Average P/E: 25.1
Negative Multiple: -205.2
14%
N/A
US
Eli Lilly and Co
NYSE:LLY
70.5
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
18%
1.1
CH
Roche Holding AG
SIX:ROG
26.2
32%
0.8
CH
Novartis AG
SIX:NOVN
17.2
17%
1
UK
AstraZeneca PLC
LSE:AZN
28.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.5
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Indoco Remedies Ltd
NSE:INDOCO
Average EV/EBITDA: 395.8
17.9
11%
1.6
US
Eli Lilly and Co
NYSE:LLY
37.8
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
14%
1
CH
Roche Holding AG
SIX:ROG
9.8
6%
1.6
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.9
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.2
8%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Indoco Remedies Ltd
NSE:INDOCO
Average EV/EBIT: 1 703.5
68.7
17%
4
US
Eli Lilly and Co
NYSE:LLY
41.3
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
CH
Novartis AG
SIX:NOVN
13.6
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.4
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
6.1
14%
0.4

See Also

Summary
INDOCO intrinsic value, competitors valuation, and company profile.
DCF Valuation
INDOCO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
INDOCO stock valuation using valuation multiples.
Wall Street Estimates
INDOCO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
INDOCO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 252,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.